Products
Desvenlafaxine has been commercially available in the United States since 2008 in the form of sustained-release tablets (Pristiq). The drug is not currently registered or available in many countries or in the EU.
Structure and properties
Desvenlafaxine (C16H25NO2, Mr = 263.4 g/mol) is present in the drug as desvenlafaxine succinate and monohydrate, a white powder that is soluble in water. It is the main active metabolite of venlafaxine (Efexor, generics). Desvenlafaxine contains one less methyl group than the parent compound and is therefore also known as O-desmethylvenlafaxine. Unlike venlafaxine, desvenlafaxine is not metabolized by CYP2D6 but is mainly conjugated.
Effects
Desvenlafaxine (ATC N06AX23) has antidepressant properties. The effects are due to potent and selective inhibition of reuptake of serotonin and norepinephrine into the presynaptic neuron.
Indications
For the treatment of depression.
Dosage
According to the professional information. The tablets are usually taken once daily and independently of meals.
Contraindications
For complete information on precautions and interactions, see the drug label.
Adverse effects
The most common possible adverse effects include nausea, dizziness, insomnia, sweating, constipation, drowsiness, reduced appetite, anxiety, and changes in sexual function in men.
